Enzyme-Cleavable Polymeric Micelles for the Intracellular Delivery of Proapoptotic Peptides.

Peptides derived from the third Bcl-2 homology domain (BH3) renormalize apoptotic signaling by antagonizing prosurvival Bcl-2 family members. These potential peptide drugs exhibit therapeutic activities but are limited by barriers including short circulation half-lives and poor penetration into cells. A diblock polymeric micelle carrier for the BIM BH3 peptide was recently described that demonstrated antitumor activity in a B-cell lymphoma xenograft model [Berguig et al., Mol. Ther. 2015, 23, 907-917]. However, the disulfide linkage used to conjugate the BIM peptide was shown to have nonoptimal blood stability. Here we describe a peptide macromonomer composed of BIM capped with a four amino acid cathepsin B substrate (FKFL) that possesses high blood stability and is cleaved to release the drug inside of target cells. Employing RAFT polymerization, the peptide macromonomer was directly integrated into a multifunctional diblock copolymer tailored for peptide delivery. The first polymer block was made as a macro-chain transfer agent (CTA) and composed of a pH-responsive endosomolytic formulation of N,N-diethylaminoethyl methacrylate (DEAEMA) and butyl methacrylate (BMA). The second polymer block was a copolymer of the peptide and polyethylene glycol methacrylate (PEGMA). PEGMA monomers of two sizes were investigated (300 Da and 950 Da). Protein gel analysis, high performance liquid chromatography, and coupled mass spectrometry (MS) showed that incubation with cathepsin B specifically cleaved the FKFL linker and released active BIM peptide with PEGMA300 but not with PEGMA950. MALDI-TOF MS showed that incubation of the peptide monomers alone in human serum resulted in partial cleavage at the FKFL linker after 12 h. However, formulation of the peptides into polymers protected against serum-mediated peptide degradation. Dynamic light scattering (DLS) demonstrated pH-dependent micelle disassembly (25 nm polymer micelles at pH 7.4 versus 6 nm unimers at pH 6.6), and a red blood cell lysis assay showed a corresponding increase in membrane destabilizing activity (<1% lysis at pH 7.4 versus 95% lysis at pH 6.6). The full carrier-drug system successfully induced apoptosis in SKOV3 ovarian cancer cells in a dose-dependent manner, in comparison to a control polymer containing a scrambled BIM peptide sequence. Mechanistic analysis verified target-dependent activation of caspase 3/7 activity (8.1-fold increase), and positive annexin V staining (72% increase). The increased blood stability of this enzyme-cleavable peptide polymer design, together with the direct polymerization approach that eliminated postsynthetic conjugation steps, suggests that this new carrier design could provide important benefits for intracellular peptide drug delivery.

[1]  P. Stayton,et al.  pH and Salt Effects on Surface Activity and Self-Assembly of Copolymers Containing a Weak Polybase. , 2016, Langmuir : the ACS journal of surfaces and colloids.

[2]  H. Frey,et al.  Biodegradable pH-Sensitive Poly(ethylene glycol) Nanocarriers for Allergen Encapsulation and Controlled Release. , 2015, Biomacromolecules.

[3]  D. Baker,et al.  Intracellular delivery system for antibody-Peptide drug conjugates. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  F. Speleman,et al.  ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. , 2014, Blood.

[5]  P. Stayton,et al.  Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[6]  David Baker,et al.  A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells , 2014, Cell.

[7]  P. Stayton,et al.  pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. , 2013, ACS nano.

[8]  S. Cory,et al.  ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. , 2013, Blood.

[9]  P. Stayton,et al.  Neutral polymeric micelles for RNA delivery. , 2013, Bioconjugate chemistry.

[10]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[11]  S. Pun,et al.  Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate. , 2012, Molecular pharmaceutics.

[12]  James D Bryers,et al.  Multifunctional triblock copolymers for intracellular messenger RNA delivery. , 2012, Biomaterials.

[13]  Jaime Rubio-Martinez,et al.  Molecular Determinants of Bim(BH3) Peptide Binding to Pro-Survival Proteins , 2012, J. Chem. Inf. Model..

[14]  K. Neoh,et al.  Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder cancer therapy. , 2012, Biomacromolecules.

[15]  Chun-Wei Peng,et al.  Cathepsin B cleavable novel prodrug Ac‐Phe‐Lys‐PABC‐ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis , 2012, Cancer.

[16]  Evripidis Gavathiotis,et al.  A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. , 2012, The Journal of clinical investigation.

[17]  P. Stayton,et al.  Diblock copolymers with tunable pH transitions for gene delivery. , 2012, Biomaterials.

[18]  D. Claxton,et al.  Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms , 2012, Expert opinion on investigational drugs.

[19]  S. Pun,et al.  Cathepsin B-sensitive polymers for compartment-specific degradation and nucleic acid release. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[20]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[21]  A. Strasser,et al.  Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases , 2011, The EMBO journal.

[22]  P. Stayton,et al.  Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  D. Benoit,et al.  Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. , 2010, Molecular pharmaceutics.

[24]  Laurent Ducry,et al.  Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.

[25]  D. Benoit,et al.  Development of a novel endosomolytic diblock copolymer for siRNA delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[26]  G. Chinnadurai,et al.  BH3-only proteins in apoptosis and beyond: an overview , 2008, Oncogene.

[27]  P. Colman,et al.  BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.

[28]  J. Lutz,et al.  Polymerization of oligo(ethylene glycol) (meth)acrylates: Toward new generations of smart biocompatible materials , 2008 .

[29]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[30]  Damon L. Meyer,et al.  Contribution of linker stability to the activities of anticancer immunoconjugates. , 2008, Bioconjugate chemistry.

[31]  Laurent Bélec,et al.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.

[32]  R. Hotchkiss,et al.  TAT-Bim Induces Extensive Apoptosis in Cancer Cells , 2007, Annals of Surgical Oncology.

[33]  James T. Elder,et al.  A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. , 2006, Cancer research.

[34]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[35]  María J Vicent,et al.  Polymer conjugates: nanosized medicines for treating cancer. , 2006, Trends in biotechnology.

[36]  Rebecca A. Roberts Lysosomal cysteine proteases: structure, function and inhibition of cathepsins. , 2005, Drug news & perspectives.

[37]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[38]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[39]  L. Juliano,et al.  Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: assays with human cathepsin B. , 2004, Analytical biochemistry.

[40]  Alfred Nordheim,et al.  Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S‐independent manner , 2004, Journal of leukocyte biology.

[41]  W. Wiczk,et al.  Fluorogenic peptide substrates for carboxydipeptidase activity of cathepsin B. , 2004, Acta biochimica Polonica.

[42]  Maurizio Pellecchia,et al.  Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL , 2004 .

[43]  J. Davies,et al.  Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 , 2004, Nature Medicine.

[44]  Hongsheng Xie,et al.  Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.

[45]  T. Kipps,et al.  Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). , 2004, Chemistry & biology.

[46]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.

[47]  D. Green,et al.  Minimal BH3 Peptides Promote Cell Death by Antagonizing Anti-apoptotic Proteins* , 2003, Journal of Biological Chemistry.

[48]  Peter D. Senter,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003 .

[49]  L. Juliano,et al.  Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides. , 2002, The Biochemical journal.

[50]  P. Trail,et al.  Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.

[51]  A. Bell,et al.  Negative Regulation of Epidermal Growth Factor Signaling by Selective Proteolytic Mechanisms in the Endosome Mediated by Cathepsin B* , 1999, The Journal of Biological Chemistry.

[52]  G. Dubowchik,et al.  Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.

[53]  P. Clarke,et al.  Regulation of apoptosis by BH3 domains in a cell-free system , 1997, Current Biology.

[54]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[55]  John Calvin Reed,et al.  Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  J. Mort,et al.  Characterization of recombinant rat cathepsin B and nonglycosylated mutants expressed in yeast. New insights into the pH dependence of cathepsin B-catalyzed hydrolyses. , 1992, The Journal of biological chemistry.

[57]  P. Stahl,et al.  Proteolytic cleavage of ricin A chain in endosomal vesicles. Evidence for the action of endosomal proteases at both neutral and acidic pH. , 1991, The Journal of biological chemistry.

[58]  D. Newell,et al.  Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. , 1988, Cancer research.

[59]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[60]  D. Blakey,et al.  New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. , 1987, Cancer research.

[61]  R. Mccauley,et al.  Glutathione , 2003, Reactions Weekly.